An oral Hemokine TM , α-methylhydrocinnamate, enhances myeloid and neutrophil recovery following irradiation in vivo

• Published in: Blood cells, molecules, & diseases molecules, & diseases, 2017-03, Vol.63, p.1
• Main Authors: Faller, Douglas V, Castaneda, Serguei A, Zhou, Daohong, Vedamony, Merriline, Newburger, Peter E, White, Gary L, Kosanke, Stanley, Plett, P Artur, Orschell, Christie M, Boosalis, Michael S, Perrine, Susan P
• Format: Article
• Language: English
• Subjects: Animals; Hematopoietic Stem Cells - drug effects; Hematopoietic Stem Cells - radiation effects; Mice; Myeloid Cells - drug effects; Myeloid Cells - radiation effects; Neutrophils - drug effects; Neutrophils - radiation effects; Papio; Phenylpropionates - pharmacology; Phenylpropionates - therapeutic use; Radiation Exposure - adverse effects; Recovery of Function - drug effects; Survival Rate; Whole-Body Irradiation - adverse effects; Whole-Body Irradiation - mortality
• ISSN: 1096-0961

An oral therapeutic which reduces duration of cytopenias and is active following accidental radiation exposures is an unmet need in radiation countermeasures. Alpha methylhydrocinnamate (ST7) prolongs STAT-5 phosphorylation, reduces growth-factor dependency of multi-lineage cell lines, and stimulates erythropoiesis. Here, ST7 and its isomers were studied for their effects on myeloid progenitors and hematopoietic stem cells (HSCs) following radiation, in nonhuman primates, and murine irradiation models. Addition of ST7 or ST7-S increased CFU-GM production by 1.7-fold (p200/mm and neutropenia recovered in 6days with ST7 treatment and 18days in controls (p